

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1617SXX

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	MAY 01	New CAS web site launched
NEWS	3	MAY 08	CA/CAPplus Indian patent publication number format defined
NEWS	4	MAY 14	RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS	5	MAY 21	BIOSIS reloaded and enhanced with archival data
NEWS	6	MAY 21	TOXCENTER enhanced with BIOSIS reload
NEWS	7	MAY 21	CA/CAPplus enhanced with additional kind codes for German patents
NEWS	8	MAY 22	CA/CAPplus enhanced with IPC reclassification in Japanese patents
NEWS	9	JUN 27	CA/CAPplus enhanced with pre-1967 CAS Registry Numbers
NEWS	10	JUN 29	STN Viewer now available
NEWS	11	JUN 29	STN Express, Version 8.2, now available
NEWS	12	JUL 02	LEMBASE coverage updated
NEWS	13	JUL 02	LMEDLINE coverage updated
NEWS	14	JUL 02	SCISEARCH enhanced with complete author names
NEWS	15	JUL 02	CHEMCATS accession numbers revised
NEWS	16	JUL 02	CA/CAPplus enhanced with utility model patents from China
NEWS	17	JUL 16	CAPplus enhanced with French and German abstracts
NEWS	18	JUL 18	CA/CAPplus patent coverage enhanced
NEWS	19	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS	20	JUL 30	USGENE now available on STN
NEWS	21	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS	22	AUG 06	BEILSTEIN updated with new compounds
NEWS	23	AUG 06	FSTA enhanced with new thesaurus edition
NEWS	24	AUG 13	CA/CAPplus enhanced with additional kind codes for granted patents
NEWS	25	AUG 20	CA/CAPplus enhanced with CAS indexing in pre-1907 records
NEWS	26	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS	27	AUG 27	USPATOLD now available on STN
NEWS	28	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS EXPRESS	29	JUNE 2007:	CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific

research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 09:19:43 ON 30 AUG 2007

=> file caplus medline embase biosis

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 09:20:07 ON 30 AUG 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 09:20:07 ON 30 AUG 2007

FILE 'EMBASE' ENTERED AT 09:20:07 ON 30 AUG 2007

Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 09:20:07 ON 30 AUG 2007

Copyright (c) 2007 The Thomson Corporation

=> s multiple sclerosis

L1 117994 MULTIPLE SCLEROSIS

=> s raloxifene or tamoxifen or lasofoxifene or idoxifene droloxifene or bazedoxifene or toremifene

L2 76609 RALOXIFENE OR TAMOXIFEN OR LASOFOXIFENE OR IDOXIFENE DROLOXIFENE OR BAZEDOXIFENE OR TOREMIFENE

=> s L1 and L2

L3 106 L1 AND L2

=> dup rem L3

PROCESSING COMPLETED FOR L3

L4 103 DUP REM L3 (3 DUPLICATES REMOVED)

=> s L4 and (AY<2004 or PY<2004 or PRY<2004)

'2004' NOT A VALID FIELD CODE

'2004' NOT A VALID FIELD CODE

2 FILES SEARCHED...

'2004' NOT A VALID FIELD CODE

'2004' NOT A VALID FIELD CODE

'2004' NOT A VALID FIELD CODE

'2004' NOT A VALID FIELD CODE

L5 64 L4 AND (AY<2004 OR PY<2004 OR PRY<2004)

=> s mammal

SYSTEM LIMITS EXCEEDED - SEARCH ENDED

L6 202198 MAMMAL

The search profile you entered was too complex or gave too many answers. Simplify or subdivide the query and try again. If you have exceeded the answer limit, enter DELETE HISTORY at an arrow prompt (=) to remove all previous answers sets and begin at L1. Use the SAVE command to store any important profiles or answer sets before using DELETE HISTORY.

=> s L5 and mammal

L7 6 L5 AND MAMMAL

=> d 1-6 L7 ibib bas  
'BAS' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS ----- GI and AB  
ALL ----- BIB, AB, IND, RE  
APPS ----- AI, PRAI  
BIB ----- AN, plus Bibliographic Data and PI table (default)  
CAN ----- List of CA abstract numbers without answer numbers  
CBIB ----- AN, plus Compressed Bibliographic Data  
CLASS ----- IPC, NCL, ECLA, FTERM  
DALL ----- ALL, delimited (end of each field identified)  
DMAX ----- MAX, delimited for post-processing  
FAM ----- AN, PI and PRAI in table, plus Patent Family data  
FBIB ----- AN, BIB, plus Patent FAM  
IND ----- Indexing data  
IPC ----- International Patent Classifications  
MAX ----- ALL, plus Patent FAM, RE  
PATS ----- PI, SO  
SAM ----- CC, SX, TI, ST, IT  
SCAN ----- CC, SX, TI, ST, IT (random display, no answer numbers;  
SCAN must be entered on the same line as the DISPLAY,  
e.g., D SCAN or DISPLAY SCAN)  
STD ----- BIB, CLASS  
  
IABS ----- ABS, indented with text labels  
IALL ----- ALL, indented with text labels  
IBIB ----- BIB, indented with text labels  
IMAX ----- MAX, indented with text labels  
ISTD ----- STD, indented with text labels  
  
OBIB ----- AN, plus Bibliographic Data (original)  
OIBIB ----- OBIB, indented with text labels  
  
SBIB ----- BIB, no citations  
SIBIB ----- IBIB, no citations  
  
HIT ----- Fields containing hit terms  
HITIND ----- IC, ICA, ICI, NCL, CC and index field (ST and IT)  
containing hit terms  
HITRN ----- HIT RN and its text modification  
HITSTR ----- HIT RN, its text modification, its CA index name, and  
its structure diagram  
HITSEQ ----- HIT RN, its text modification, its CA index name, its  
structure diagram, plus NTE and SEQ fields  
FHITSTR ----- First HIT RN, its text modification, its CA index name, and  
its structure diagram  
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its  
structure diagram, plus NTE and SEQ fields  
KWIC ----- Hit term plus 20 words on either side  
OCC ----- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.  
ENTER DISPLAY FORMAT (BIB):end

=> d 1-6 L7 ibib abs

L7 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:239153 CAPLUS

DOCUMENT NUMBER: 142:292531

TITLE: Manufacture of therapeutic proteins as fusion proteins in the mammary gland with secretion into milk for purification

INVENTOR(S): Meade, Harry; Cox, Geoffrey F.

PATENT ASSIGNEE(S): GTC Biotherapeutics, Inc., USA

SOURCE: PCT Int. Appl., 127 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005024044	A2	20050317	WO 2004-US29128	20040903 <--
WO 2005024044	A3	20050602		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004271200	A1	20050317	AU 2004-271200	20040903 <--
CA 2537273	A1	20050317	CA 2004-2537273	20040903 <--
US 2006105347	A1	20060518	US 2004-933854	20040903 <--
EP 1670931	A2	20060621	EP 2004-783398	20040903 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
CN 1871252	A	20061129	CN 2004-80030708	20040903 <--
JP 2007503838	T	20070301	JP 2006-525523	20040903 <--
PRIORITY APPLN. INFO.:			US 2003-500910P	P 20030905 <--
			WO 2004-US29128	W 20040903

AB Fusion proteins of valuable or useful proteins can be produced in the mammary gland and purified from the milk of transgenic animals. The peptides are made as fusion proteins with a suitable fusion partner such as human  $\alpha$ -fetoprotein. The fusion partner protein increases the half-life of the fusion product and may itself have therapeutic effects. The fusion protein can be purified from the milk or other body fluids by affinity methods. A particular advantage of producing peptides via this route, in addition to the obvious advantages of high yield and biocompatibility, is that specific post-translational modifications, such as carboxy terminal amidation, can be performed in the mammary gland. Methods of developing transgenic mammals and characterizing them, methods of constructing expression systems and methods of purifying proteins from milk are discussed.

L7 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:606368 CAPLUS

DOCUMENT NUMBER: 141:134076

TITLE: The use of estrogen receptor alpha modulators for the treatment of multiple sclerosis

INVENTOR(S): Elloso, M. Merle; Mitchell, Robert; Harnish, Douglas C.; Adelman, Steven J.

PATENT ASSIGNEE(S): Wyeth, John, and Brother Ltd., USA  
 SOURCE: PCT Int. Appl., 30 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004062653	A2	20040729	WO 2004-US37	20040105 <--
WO 2004062653	A3	20041104		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ				
AU 2004204675	A1	20040729	AU 2004-204675	20040105 <--
CA 2512021	A1	20040729	CA 2004-2512021	20040105 <--
US 2004167112	A1	20040826	US 2004-751543	20040105 <--
EP 1585507	A2	20051019	EP 2004-700191	20040105 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2004006643	A	20051206	BR 2004-6643	20040105 <--
CN 1723013	A	20060118	CN 2004-80001876	20040105 <--
JP 2006515616	T	20060601	JP 2006-500772	20040105 <--
IN 2005DN02774	A	20070420	IN 2005-DN2774	20050622 <--
NO 2005003156	A	20050908	NO 2005-3156	20050628 <--
MX 2005PA07317	A	20050930	MX 2005-PA7317	20050705 <--
PRIORITY APPLN. INFO.: US 2003-438123P P 20030106 <--				
WO 2004-US37 W 20040105				

AB The present invention provides methods of treating an autoimmune pathol. in a mammal, comprising administering an agent with estrogen receptor- $\alpha$  agonist activity in particular a selective estrogen receptor modulator, to the mammal in an amount sufficient to decrease production of TH-1 and/or TH-2 cytokines. Also provided is a method of selecting compds. useful for the treatment of multiple sclerosis, comprising selecting a compound which has estrogen receptor- $\alpha$  agonist activity.

L7 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:473335 CAPLUS  
 DOCUMENT NUMBER: 141:33812  
 TITLE: Methods for modulating mammalian cell survival by modulating huntingtin protein function, and uses in therapy, prophylaxis and diagnosis  
 INVENTOR(S): Hayden, Michael; Hackam, Abigail; Leavitt, Blair R.; Chan, Edmond  
 PATENT ASSIGNEE(S): Can.  
 SOURCE: U.S. Pat. Appl. Publ., 66 pp., Cont.-in-part of U.S. Pat. Appl. 2002 187,931.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004110676	A1	20040610	US 2003-419997	20030422 <--
WO 2001079283	A1	20011025	WO 2001-CA495	20010412 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,				

RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,  
 VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2002187931 A1 20021212 US 2002-9478 20020531 <--  
 CA 2424577 A1 20031022 CA 2003-2424577 20030422 <--  
 PRIORITY APPLN. INFO.: CA 2000-2305088 A 20000413 <--  
 CA 2000-2326543 A 20001212 <--  
 WO 2001-CA495 W 20010412 <--  
 US 2002-374156P P 20020422 <--  
 US 2002-9478 A2 20020531 <--

AB The present invention provides methods of modulating cell survival by modulating wild-type huntingtin (HTT) protein function. The invention provides methods of treatment or prophylaxis of a cell degenerative or proliferative diseases by administering a HTT protein or a biol.-active fragment or variant thereof. In various alternative aspects, the invention provides diagnostic assays or methods of assaying test compds. using a HTT protein or a biol.-active fragment or variant thereof. HTT was shown to reduce apoptosis and aggregation in neuronal cells. Wild-type HTT reduces the cellular toxicity of mutant huntingtin in mice. Antagonists of HTT protein decrease the pro-survival function of the HTT and thereby reduce abnormal cell proliferation. Thus, the invention provides for means to activate or attenuate cell death within tissue, in order to facilitate the treatment of conditions where there is a dysregulation of cell death or cellular proliferation. Therapeutic application of this invention pertains to diseases and disorders including, but not limited to, Huntington disease, neurodegenerative diseases, stroke, and cancer.

L7 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1998:708808 CAPLUS  
 DOCUMENT NUMBER: 129:310911  
 TITLE: TGF- $\beta$ -elevating compounds and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods  
 INVENTOR(S): Grainger, David J.; Metcalfe, James C.; Kasina, Sudhakar  
 PATENT ASSIGNEE(S): Neorx Corp., USA  
 SOURCE: PCT Int. Appl., 153 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9846588	A2	19981022	WO 1998-US7063	19980409 <--
WO 9846588	A3	19990107		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9869598	A	19981111	AU 1998-69598	19980409 <--
US 6117911	A	20000912	US 1998-57323	19980409 <--
US 6410587	B1	20020625	US 2000-567558	20000505 <--
US 2003064970	A1	20030403	US 2002-170971	20020613 <--
US 6734208	B2	20040511		
US 2005020667	A1	20050127	US 2004-827602	20040419 <--

US 7084171 B2 20060801  
 US 2006084696 A1 20060420 US 2005-270185 20051109 <--  
 PRIORITY APPLN. INFO.: US 1997-43852P P 19970411 <--  
 US 1998-57323 A1 19980409 <--  
 WO 1998-US7063 W 19980409 <--  
 US 2000-567558 A3 20000505 <--  
 US 2002-170971 A3 20020613 <--  
 US 2004-827602 A3 20040419

OTHER SOURCE(S): MARPAT 129:310911

AB A method is provided for treating a mammal having, or at risk of, an indication associated with a TGF- $\beta$  deficiency, comprising administering one or more agents that is effective to elevate the level of TGF- $\beta$ . The invention also provides compds. that elevate TGF-beta levels, as well as pharmaceutical compns. comprising compds. that elevate TGF-beta levels and methods for detecting diseases associated with endothelial cell activation.

L7 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1998:484940 CAPLUS  
 DOCUMENT NUMBER: 129:104235  
 TITLE: Tricarboxylic acid-containing oxyalkyl esters, and therapeutic uses thereof  
 INVENTOR(S): Nudelman, Abraham; Rephaeli, Ada  
 PATENT ASSIGNEE(S): Beacon Laboratories L.L.C., USA  
 SOURCE: PCT Int. Appl., 64 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9829114	A1	19980709	WO 1997-US23725	19971230 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 6130248	A	20001010	US 1996-781905	19961230 <--
AU 9856173	A	19980731	AU 1998-56173	19971230 <--
EP 961614	A1	19991208	EP 1997-952599	19971230 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

PRIORITY APPLN. INFO.: US 1996-781905 A 19961230 <--  
 US 1997-814365 A 19970311 <--  
 WO 1997-US23725 W 19971230 <--

OTHER SOURCE(S): MARPAT 129:104235

AB Compns. for and methods of treating, preventing or ameliorating cancer and other proliferative diseases are provided, as are methods of inducing wound healing, treating cutaneous ulcers, treating gastrointestinal disorders, treating blood disorders such as anemias, immunomodulation, enhancing recombinant gene expression, treating insulin-dependent patients, treating cystic fibrosis patients, inhibiting telomerase activity, treating virus-associated tumors, especially EBV-associated tumors, modulating gene expression and particularly augmenting expression of tumor suppressor genes, inducing tolerance to antigens; treating, preventing, or ameliorating protozoan infection or inhibiting histone deacetylase in cells. The methods of the invention use tricarboxylic acid substituted oxyalkyl esters.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1994:45925 CAPLUS  
DOCUMENT NUMBER: 120:45925  
TITLE: Evaluative means for detecting inflammatory reactivity  
INVENTOR(S): Sternberg, Esther M.; Gold, Philip W.; Page, Samuel W.  
PATENT ASSIGNEE(S): United States Dept. of Health and Human Services, USA  
SOURCE: PCT Int. Appl., 45 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9322685	A1	19931111	WO 1993-US4070	19930505 <--
W: AU, CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2067123	A1	19910326	CA 1990-2067123	19900925 <--
WO 9104479	A1	19910404	WO 1990-US5457	19900925 <--
W: AU, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE				
AU 9065374	A	19910418	AU 1990-65374	19900925 <--
AU 648274	B2	19940421		
EP 494256	A1	19920715	EP 1990-915568	19900925 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
JP 04504760	T	19920820	JP 1990-514350	19900925 <--
US 5348729	A	19940920	US 1992-878608	19920505 <--
AU 9342253	A	19931129	AU 1993-42253	19930505 <--
PRIORITY APPLN. INFO.:			US 1992-878608	A 19920505 <--
			US 1988-277708	A2 19881130 <--
			US 1989-365735	B2 19890614 <--
			US 1989-412294	A 19890925 <--
			US 1989-422791	A 19891018 <--
			WO 1990-US5457	A 19900925 <--
			WO 1993-US4070	A 19930505 <--

AB A method for testing the susceptibility of a mammal to inflammatory diseases comprises (1) administering to a mammal a compound selected from the group consisting of type I mineralocorticoid receptor antagonists, opiate antagonists, estrogen antagonists or mixed estrogen agonists/antagonists, progesterone agonists; or a combination of an estrogen antagonist with I or a combination of a type I glucocorticoid receptor antagonist, a type II glucocorticoid agonist or a progesterone agonist which is effective in stimulating the hypothalamic-pituitary-adrenal axis; and (2) measuring the level of  $\geq 1$  hormone secreted by the hypothalamus, pituitary or adrenal glands. Also disclosed are methods of treating inflammatory diseases and atypical depression. Chronic treatment of rats with mepresone (a type I glucocorticoid receptor antagonist) or tamoxifen (an estrogen receptor antagonist) significantly suppressed their inflammatory response to carrageenan.

=> s L5 and SERM

L8 1 L5 AND SERM

=> s selective estrogen receptor modulator

L9 9111 SELECTIVE ESTROGEN RECEPTOR MODULATOR

=> s L5 and L9

L10 4 L5 AND L9

=> dup rem L10



PROCESSING COMPLETED FOR L10  
L11 4 DUP REM L10 (0 DUPLICATES REMOVED)

=> d 1-4 ibib abs

L11 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2005:490384 CAPLUS  
DOCUMENT NUMBER: 143:42681  
TITLE: Anti-IGFR-1 antibodies in combination with  
chemotherapeutic agent for treating cancer  
INVENTOR(S): Wang, Yan; Pachter, Jonathan A.; Bishop, Walter R.  
PATENT ASSIGNEE(S): Schering Corporation, USA  
SOURCE: PCT Int. Appl., 97 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005052005	A1	20050609	WO 2004-US38842	20041119 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004292554	A1	20050609	AU 2004-292554	20041119 <--
CA 2546664	A1	20050609	CA 2004-2546664	20041119 <--
US 2005136063	A1	20050623	US 2004-993395	20041119 <--
EP 1689782	A1	20060816	EP 2004-811545	20041119 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU			
CN 1906214	A	20070131	CN 2004-80040801	20041119 <--
IN 2006CN01763	A	20070706	IN 2006-CN1763	20060519 <--
MX 2006PA05779	A	20060714	MX 2006-PA5779	20060522 <--
NO 2006002885	A	20060818	NO 2006-2885	20060620 <--
PRIORITY APPLN. INFO.:			US 2003-524732P P 20031121 <--	
			WO 2004-US38842 W 20041119	


AB The present invention provides combinations including a binding composition, such as an anti-IGFR1 antibody, in association with a chemotherapeutic agent. The antibody is e.g. a human monoclonal antibody recognizing human IGFR-1, especially soluble IGFR-1. The chemotherapeutic agent is selected from a taxane, topoisomerase inhibitor, signal transduction inhibitor, cell cycle inhibitor, farnesyl protein transferase inhibitor, EGFR inhibitor, HER2 inhibitor, VEGFR inhibitor, MAP kinase inhibitor, MEK kinase inhibitor, AKT kinase inhibitor, mTOR inhibitor, etc. Methods for using the combinations to treat medical conditions, such as cancer, are also provided.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2005:409303 CAPLUS  
DOCUMENT NUMBER: 142:457099  
TITLE: Development of new selective

estrogen receptor modulators  
 INVENTOR(S): Scanlan, Thomas S.; Kelly, Martin J.; Qiu, Jian;  
 Tobias, Sandra; Ronnekleiv, Oline K.  
 PATENT ASSIGNEE(S): The Regents of the University of California, USA;  
 Oregon Health & Science University  
 SOURCE: PCT Int. Appl., 88 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005041946	A1	20050512	WO 2004-US34921	20041021 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005113453	A1	20050526	US 2004-970242	20041020 <--
US 7196119	B2	20070327		
AU 2004284945	A1	20050512	AU 2004-284945	20041021 <--
CA 2538939	A1	20050512	CA 2004-2538939	20041021 <--
EP 1680101	A1	20060719	EP 2004-795992	20041021 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
JP 2007509858	T	20070419	JP 2006-536795	20041021 <--
PRIORITY APPLN. INFO.:			US 2003-513235P	P 20031021 <--
			US 2004-970242	A 20041020
			WO 2004-US34921	W 20041021
OTHER SOURCE(S):		MARPAT 142:457099		
GI				



AB The present disclosure concerns a new class of selective estrogen receptor modulators (SERMs) with formula I (where R = H, lower aliphatic group; M = amide, ketone, etc., X = OH, alkoxy, halogen; Y = a heteroatom; G = linker group; Z = OH, NH<sub>2</sub>, etc.). The disclosure also includes the identification of a previously unknown membrane associated estrogen receptor. Methods for making and using the disclosed SERMs are disclosed, including pharmaceutical formulations of the disclosed novel compds. in useful compns.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2004:606368 CAPLUS  
 DOCUMENT NUMBER: 141:134076  
 TITLE: The use of estrogen receptor alpha modulators for the treatment of multiple sclerosis  
 INVENTOR(S): Elloso, M. Merle; Mitchell, Robert; Harnish, Douglas C.; Adelman, Steven J.  
 PATENT ASSIGNEE(S): Wyeth, John, and Brother Ltd., USA  
 SOURCE: PCT Int. Appl., 30 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004062653	A2	20040729	WO 2004-US37	20040105 <--
WO 2004062653	A3	20041104		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ				
AU 2004204675	A1	20040729	AU 2004-204675	20040105 <--
CA 2512021	A1	20040729	CA 2004-2512021	20040105 <--
US 2004167112	A1	20040826	US 2004-751543	20040105 <--
EP 1585507	A2	20051019	EP 2004-700191	20040105 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2004006643	A	20051206	BR 2004-6643	20040105 <--
CN 1723013	A	20060118	CN 2004-80001876	20040105 <--
JP 2006515616	T	20060601	JP 2006-500772	20040105 <--
IN 2005DN02774	A	20070420	IN 2005-DN2774	20050622 <--
NO 2005003156	A	20050908	NO 2005-3156	20050628 <--
MX 2005PA07317	A	20050930	MX 2005-PA7317	20050705 <--
PRIORITY APPLN. INFO.:			US 2003-438123P	P 20030106 <--
			WO 2004-US37	W 20040105

AB The present invention provides methods of treating an autoimmune pathol. in a mammal, comprising administering an agent with estrogen receptor- $\alpha$  agonist activity in particular a selective estrogen receptor modulator, to the mammal in an amount sufficient to decrease production of TH-1 and/or TH-2 cytokines.  
 Also provided is a method of selecting compds. useful for the treatment of multiple sclerosis, comprising selecting a compound which has estrogen receptor- $\alpha$  agonist activity.

L11 ANSWER 4 OF 4 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2002168036 EMBASE  
 TITLE: Maximizing health in menopausal women with disabilities.  
 AUTHOR: Welner S.L.; Simon J.A.; Welner B.  
 CORPORATE SOURCE: Dr. J.A. Simon, 1140 19th Street, Washington, DC 20063, United States. jasimon@whrc.net  
 SOURCE: Menopause, (2002) Vol. 9, No. 3, pp. 208-219. .  
 Refs: 164  
 ISSN: 1072-3714 CODEN: MENOF2  
 COUNTRY: United States  
 DOCUMENT TYPE: Journal; Article  
 FILE SEGMENT: 010 Obstetrics and Gynecology  
 017 Public Health, Social Medicine and Epidemiology  
 037 Drug Literature Index  
 LANGUAGE: English  
 SUMMARY LANGUAGE: English  
 ENTRY DATE: Entered STN: 23 May 2002

Last Updated on STN: 23 May 2002

AB There are nearly 30 million women with disabilities in the United States. Of these, more than 16 million are over the age of 50. Years ago, women with disabilities did not commonly live to the age of menopause, and, if they did, they reached this stage of life in a very debilitated condition. Now, women with disabilities are entering their mature years as active members of society who can look forward to productive futures. Because the health needs of women with disabilities might differ from those of other women, special attention should be focused on how physiological changes of perimenopausal and menopausal states affect this population. In addition to functional changes that might affect menopausal women with disabilities, basic health maintenance issues may be adversely affected by environmental factors. Physical barriers can influence compliance with preventive health screening that is essential in aging populations. Treatment options might need to be tailored to the individual. The disabling condition itself may progress, resulting in secondary conditions requiring creative interventions. A comprehensive evaluation and the development of a suitable management plan, which takes into account the multifactorial nature of aging as a disabled woman, are essential in delivering optimal care to this population.

=> s L5 NOT L7

L12 58 L5 NOT L7

=> d 1-20 L12 ibib abs

L12 ANSWER 1 OF 58 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:383729 CAPLUS

DOCUMENT NUMBER: 146:344436

TITLE: Composition comprising olive kernel extract for treatment of inflammatory disease

INVENTOR(S): Theoharides, Theoharis C.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 8pp., Cont.-in-part of U.S. Ser. No. 811,859.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 7

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2007077317	A1	20070405	US 2006-519965	20060913
US 2005042312	A1	20050224	US 2004-811859	20040330 <--
PRIORITY APPLN. INFO.:			US 2004-811859	B2 20040330
			US 1998-56707	A1 19980408 <--
			US 2001-771669	A1 20010130 <--
			WO 2002-US476	A1 20020103 <--

AB The claimed invention is composition comprising an organic extract of de-fleshed,

purified, isolated olive kernels that contains one or more components that increase absorption of macromols. such as proteoglycans across cell membranes, that have antioxidant properties, and that have anti-inflammatory effects in tissues. Thus, capsule was prepared containing chondroitin sulfate 150-300 mg, D-glucosamine sulfate 150-300 mg, quercetin 150-300 mg and olive kernel extract 350-1200 mg.

L12 ANSWER 2 OF 58 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:172165 CAPLUS

DOCUMENT NUMBER: 144:318528

TITLE: Compositions and methods for the treatment of autoimmune diseases and neurological disorders

PATENT ASSIGNEE(S): Dan Milder, Australia  
SOURCE: Aust. Pat. Appl., 26 pp.  
CODEN: AUXXCM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
AU 2003204344	A1	20031211	AU 2003-204344	20030523 <--
PRIORITY APPLN. INFO.:			AU 2002-2492	A 20020523 <--
AB	Compns. for the treatment of autoimmune diseases and neurol. disorders, such as multiple sclerosis and Alzheimer's disease, which comprises one or more immunosuppressive agents in association with one or more immunomodulatory compds. are described. Also described are methods for the treatment of autoimmune diseases and neurol. disorders utilizing compns. of the invention. A pharmaceutical formulation contained 25 mg azathioprine, and 250 µg (8 million units) β-interferon. A 50 yr old woman with progressive multiple sclerosis was administered 25 mg azathioprine orally daily and 8 million units by s.c. injection of interferon beta daily. The patient experienced sustained visual improvement, improved cerebellar functions, and increased rationality and diminished "disingibition" when tested at seven weeks.			

L12 ANSWER 3 OF 58 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2005:1077920 CAPLUS  
DOCUMENT NUMBER: 143:353411  
TITLE: Anti-inflammatory compositions for multiple sclerosis  
INVENTOR(S): Theoharides, Theoharis C.  
PATENT ASSIGNEE(S): USA  
SOURCE: U.S. Pat. Appl. Publ., 9 pp.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 7  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005220908	A1	20051006	US 2004-811826	20040330
US 2006013905	A1	20060119	US 2005-214831	20050831 <--
PRIORITY APPLN. INFO.:			US 1998-56707	A2 19980408 <--
			US 2001-771669	A2 20010130 <--
			WO 2002-US476	A2 20020103 <--
			US 2004-811826	A2 20040330
AB	Compns. with synergistic anti-inflammatory effects in inflammatory diseases resulting from activation and consequent degranulation of mast cells and followed by secretion of inflammatory biomols. from the activated mast cells, composed of a heavily sulfated, non-bovine proteoglycan such as shark cartilage chondroitin sulfate C, an unrefined olive kernel oil extract that increases absorption of these compns. in various routes of administration, and one or more of a hexosamine sulfate such as D-glucosamine sulfate, a flavone such as quercetin, S-adenosylmethionine, a histamine-1 receptor antagonist, a histamine-3 receptor agonist, an antagonist of the actions of CRH, caffeine, and a polyamine.			

L12 ANSWER 4 OF 58 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2005:490384 CAPLUS  
DOCUMENT NUMBER: 143:42681  
TITLE: Anti-IGFR-1 antibodies in combination with

INVENTOR(S): chemotherapeutic agent for treating cancer  
 PATENT ASSIGNEE(S): Wang, Yan; Pachter, Jonathan A.; Bishop, Walter R.  
 SOURCE: Schering Corporation, USA  
 PCT Int. Appl., 97 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005052005	A1	20050609	WO 2004-US38842	20041119 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004292554	A1	20050609	AU 2004-292554	20041119 <--
CA 2546664	A1	20050609	CA 2004-2546664	20041119 <--
US 2005136063	A1	20050623	US 2004-993395	20041119 <--
EP 1689782	A1	20060816	EP 2004-811545	20041119 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU				
CN 1906214	A	20070131	CN 2004-80040801	20041119 <--
IN 2006CN01763	A	20070706	IN 2006-CN1763	20060519 <--
MX 2006PA05779	A	20060714	MX 2006-PA5779	20060522 <--
NO 2006002885	A	20060818	NO 2006-2885	20060620 <--
PRIORITY APPLN. INFO.:			US 2003-524732P	P 20031121 <--
			WO 2004-US38842	W 20041119

AB The present invention provides combinations including a binding composition,  
 such as an anti-IGFR1 antibody, in association with a chemotherapeutic agent.  
 The antibody is e.g. a human monoclonal antibody recognizing human IGFR-1,  
 especially soluble IGFR-1. The chemotherapeutic agent is selected from a  
 taxane,  
 topoisomerase inhibitor, signal transduction inhibitor, cell cycle  
 inhibitor, farnesyl protein transferase inhibitor, EGFR inhibitor, HER2  
 inhibitor, VEGFR inhibitor, MAP kinase inhibitor, MEK kinase inhibitor,  
 AKT kinase inhibitor, mTOR inhibitor, etc. Methods for using the  
 combinations to treat medical conditions, such as cancer, are also  
 provided.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 5 OF 58 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:423722 CAPLUS  
 DOCUMENT NUMBER: 142:469160  
 TITLE: pH sensitive prodrugs of 2,6-diisopropylphenol  
 INVENTOR(S): Marappan, Subramanian; Davenport, Cris; Sarshar,  
 Sepehr  
 PATENT ASSIGNEE(S): Auspex Pharmaceuticals, Inc., USA  
 SOURCE: PCT Int. Appl., 61 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005044201	A2	20050519	WO 2004-US7935	20040315 <--
WO 2005044201	A3	20051103		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004286814	A1	20050519	AU 2004-286814	20040315 <--
CA 2543166	A1	20050519	CA 2004-2543166	20040315 <--
EP 1680409	A2	20060719	EP 2004-818276	20040315 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1882548	A	20061220	CN 2004-80033885	20040315 <--
US 2005234050	A1	20051020	US 2005-514303	20050617 <--
US 7250412	B2	20070731		

PRIORITY APPLN. INFO.: US 2003-514340P P 20031024 <--  
 WO 2004-US7935 W 20040315

OTHER SOURCE(S): CASREACT 142:469160; MARPAT 142:469160

AB The present invention is directed to water-soluble derivs. of 2,6-diisopropylphenol (propofol). The compds. act as prodrugs of 2,6-diisopropylphenol and metabolize rapidly to propofol thereby providing an alternative to the water-insol. 2,6-diisopropylphenol. Pharmaceutical compns. comprising these compds., methods of induction and maintenance of anesthesia or sedation as well as methods of treating neurodegenerative diseases utilizing pharmaceutical compns. comprising these compds. and methods of preparing them are also disclosed. N-(2-Piperidin-1-yl-ethyl)-succinamic acid 2,6-diisopropylphenyl ester was obtained by the reaction of propofol hemisuccinate with 1-(2-aminoethyl)pyrrolidine, then it was reacted with HCl to obtain hydrochloride salt (I). Efficacy of I at 150 mg/kg in induction of anesthesia in mice are shown.

L12 ANSWER 6 OF 58 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:409303 CAPLUS

DOCUMENT NUMBER: 142:457099

TITLE: Development of new selective estrogen receptor modulators

INVENTOR(S): Scanlan, Thomas S.; Kelly, Martin J.; Qiu, Jian; Tobias, Sandra; Ronnekleiv, Oline K.

PATENT ASSIGNEE(S): The Regents of the University of California, USA; Oregon Health & Science University

SOURCE: PCT Int. Appl., 88 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005041946	A1	20050512	WO 2004-US34921	20041021 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,				


TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,  
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
 SN, TD, TG

US 2005113453 A1 20050526 US 2004-970242 20041020 <--  
 US 7196119 B2 20070327  
 AU 2004284945 A1 20050512 AU 2004-284945 20041021 <--  
 CA 2538939 A1 20050512 CA 2004-2538939 20041021 <--  
 EP 1680101 A1 20060719 EP 2004-795992 20041021 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

JP 2007509858 T 20070419 JP 2006-536795 20041021 <--  
 PRIORITY APPLN. INFO.: US 2003-513235P P 20031021 <--  
 US 2004-970242 A 20041020  
 WO 2004-US34921 W 20041021

OTHER SOURCE(S): MARPAT 142:457099  
 GI



AB The present disclosure concerns a new class of selective estrogen receptor modulators (SERMs) with formula I (where R = H, lower aliphatic group; M = amide, ketone, etc., X = OH, alkoxy, halogen; Y = a heteroatom; G = linker group; Z = OH, NH<sub>2</sub>, etc.). The disclosure also includes the identification of a previously unknown membrane associated estrogen receptor. Methods for making and using the disclosed SERMs are disclosed, including pharmaceutical formulations of the disclosed novel compds. in useful compns.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 7 OF 58 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:347136 CAPLUS

DOCUMENT NUMBER: 142:409698

TITLE: Vaccines for cancer, autoimmune disease and infections

INVENTOR(S): Molldrem, Jeffrey

PATENT ASSIGNEE(S): Board of Regents, the University of Texas System, USA

SOURCE: PCT Int. Appl., 235 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005035714	A2	20050421	WO 2004-US27792	20040826 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,				



TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW  
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,  
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
SN, TD, TG

EP 1670899 A2 20060621 EP 2004-809624 20040826 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

PRIORITY APPLN. INFO.: US 2003-498238P P 20030826 <--  
WO 2004-US27792 W 20040826

AB The author discloses tumor-associated HLA-restricted peptides for treating or preventing cancers in a patient. In specific aspects, the peptides are derived from neutrophil elastase, cyclin E1, cyclin D, or cyclin E2. Such peptides can be used to elicit specific CTLs that preferentially attack tumor cells (e.g., myeloid leukemia). The present invention also provides HLA-restricted antigens as vaccines for treating or preventing autoimmune diseases or conditions, transplant rejection or vasculitis. In particular aspects, there is provided PR3, a myeloid tissue-restricted protein and a HLA-A2.1-restricted self-peptide, PR1, derived from PR3, which can be used to elicit PR1-specific CTLs.

L12 ANSWER 8 OF 58 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:316322 CAPLUS

DOCUMENT NUMBER: 142:367705

TITLE: Site and rate selective prodrug formulations of D609 with antioxidant and anticancer activity

INVENTOR(S): Meier, G. Patrick; Bai, Aiping; Zhou, Daohong

PATENT ASSIGNEE(S): MUSC Foundation for Research Development, USA

SOURCE: PCT Int. Appl., 86 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005032492	A2	20050414	WO 2004-US33255	20041008 <--
WO 2005032492	A3	20070412		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, US			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, AP, EA, EP, OA			

PRIORITY APPLN. INFO.: US 2003-509700P P 20031008 <--

OTHER SOURCE(S): MARPAT 142:367705

AB Comps. that are heteroatom substituted alkyl derivs. of tricyclodecan-9-yl-xanthogenate (D609), and pharmaceutical compns. of these compds., are disclosed. Methods of treating a disease or disorder in a subject and methods of protecting normal tissues in a subject from toxicity associated ionizing radiation or chemotherapy using compns. comprising these novel compds. are also disclosed. The invention also concerns methods of treating a disease or disorder in a subject using compns. that include these novel compds. while concurrently or consecutively treating the subject with ionizing radiation or a chemotherapeutic agent.

L12 ANSWER 9 OF 58 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:141088 CAPLUS

DOCUMENT NUMBER: 142:217397

TITLE: Bispecific antibodies for inducing apoptosis of tumor and diseased cells

INVENTOR(S): Chang, Chien-Hsing; Goldenberg, David M.; Hansen, Hans J.; Horak, Eva; Horak, Ivan

PATENT ASSIGNEE(S): Immunomedics, Inc., USA

SOURCE: PCT Int. Appl., 60 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005014618	A2	20050217	WO 2004-US25840	20040809 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004263538	A1	20050217	AU 2004-263538	20040809 <--
CA 2534898	A1	20050217	CA 2004-2534898	20040809 <--
US 2005079184	A1	20050414	US 2004-913509	20040809 <--
EP 1651663	A2	20060503	EP 2004-780644	20040809 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
JP 2007516213	T	20070621	JP 2006-523297	20040809 <--
PRIORITY APPLN. INFO.:			US 2003-493365P	P 20030808 <--
			WO 2004-US25840	W 20040809

AB The authors disclose bispecific antibodies in the form of heteroconjugates that inhibit growth and induce apoptosis of a diseased cell and that do not require the recruitment of effector cells. The heteroconjugate has at least two binding arms wherein each of the binding arms possesses a different specificity and need not have apoptotic activity when not conjugated to each other. In one example, the heteroconjugate is composed of an Fab' fragment targeting CD20 joined to a second Fab' fragment targeting CD22. Also provided are methods of treating and diagnosing a diseased cell using the bispecific antibodies of the present invention.

L12 ANSWER 10 OF 58 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:122803 CAPLUS

DOCUMENT NUMBER: 142:219083

TITLE: Preparation of phosphorus-containing rapamycin derivatives for use in pharmaceutical compositions as immunosuppressive and anticancer agents

INVENTOR(S): Metcalf, Chester A., III; Rozamus, Leonard W.; Wang, Yihan; Berstein, David L.

PATENT ASSIGNEE(S): Ariad Gene Therapeutics, Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 57 pp., Cont.-in-part of U.S. Ser. No. 635,054.

CODEN: USXXCO


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005032825	A1	20050210	US 2004-862149	20040604 <--
US 7091213	B2	20060815		
US 2003220297	A1	20031127	US 2003-357152	20030203 <--
US 2004073024	A1	20040415	US 2003-635054	20030806 <--
US 2006264405	A1	20061123	US 2006-429582	20060505 <--
US 2006264456	A1	20061123	US 2006-494418	20060727 <--
US 7186826	B2	20070306		
US 2007190106	A1	20070816	US 2007-650017	20070105 <--
PRIORITY APPLN. INFO.:			US 2002-353252P	P 20020201 <--
			US 2002-426928P	P 20021115 <--
			US 2002-428383P	P 20021122 <--
			US 2002-433930P	P 20021217 <--
			US 2003-357152	A2 20030203 <--
			US 2003-635054	A2 20030806 <--
			US 2003-486367P	P 20030711 <--
			US 2004-862149	A2 20040604
			US 2004-889163	B2 20040712
			US 2005-711859P	P 20050826
			US 2006-494418	A1 20060727
OTHER SOURCE(S):			CASREACT 142:219083; MARPAT 142:219083	
GI				



AB Rapamycin derivs. containing phosphorus moiety, such as I [A = O, S, NR<sub>2</sub>, absent; Q = V, OV, SV, NR<sub>2</sub>, absent; V = aliphatic, heteroaliph., aryl, heteroaryl moiety, such that J is linked to the cyclohexyl ring directly, through A or through VA, OVA, SVA or NR<sub>2</sub>VA; J = P(:K)(YR<sub>5</sub>)<sub>2</sub>, P(YR<sub>5</sub>)<sub>2</sub>, P(:K)(YR<sub>5</sub>)GR<sub>6</sub>; K = O, S; Y = O, S, NR<sub>2</sub>, bond; R<sub>2</sub>, R<sub>5</sub> = aliphatic, heteroaliph., aryl, heteroaryl, H; R<sub>6</sub> = PK(YR<sub>5</sub>)YR<sub>5</sub>, SO<sub>2</sub>YR<sub>5</sub>, C(O)YR<sub>5</sub>; G = O, S, NR<sub>2</sub>, (M)X; M = (un)substituted methylene, alkyl, alkylene; X = 1-6], and pharmaceutically acceptable derivs. thereof, were prepared for therapeutic use as immunosuppressive and anticancer agents. These rapamycin derivs. are useful for treatment of graft vs. host disease, lupus, rheumatoid arthritis, diabetes mellitus, myasthenia gravis, multiple sclerosis, psoriasis, dermatitis, eczema, seborrhea, inflammatory bowel disease, pulmonary inflammation, ocular uveitis; adult T-cell leukemia, lymphoma, fungal infections, hyperproliferative restenosis, graft vascular atherosclerosis, coronary artery disease, cerebrovascular disease, arteriosclerosis; atherosclerosis, nonatheromatous arteriosclerosis, or vascular wall damage

from cellular events leading toward immune mediated vascular damage, stroke or multi-infarct dementia. Thus, I [A-QJ = OP(O)(OBu)Me] was prepared by reacting rapamycin with methylphosphonic dichloride and n-butanol using 3,5-lutidine in CH<sub>2</sub>Cl<sub>2</sub> under a nitrogen atmospheric Binding affinity of the rapamycin phosphorus derivs. for human FKBP-12 protein was assayed, dosages for restenosis prevention were discussed.

REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 11 OF 58 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:99470 CAPLUS

DOCUMENT NUMBER: 142:197889

TITLE: Fluoro substituted omega-carboxyaryl diphenyl urea for treatment of raf, VEGFR, PDGFR, p38 and flt-3 kinase-mediated diseases

INVENTOR(S): Dumas, Jacques; Boyer, Stephen; Riedl, Bernd; Wilhelm, Scott

PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA

SOURCE: PCT Int. Appl., 68 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005009961	A2	20050203	WO 2004-US23500	20040722 <--
WO 2005009961	A3	20050331		
W:				
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:				
BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004259760	A1	20050203	AU 2004-259760	20040722 <--
CA 2532865	A1	20050203	CA 2004-2532865	20040722 <--
US 2005038080	A1	20050217	US 2004-895985	20040722 <--
EP 1663978	A2	20060607	EP 2004-786091	20040722 <--
R:				
AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR 2004012219	A	20060822	BR 2004-12219	20040722 <--
CN 1856469	A	20061101	CN 2004-80021091	20040722 <--
JP 2006528196	T	20061214	JP 2006-521221	20040722 <--
MX 2006PA00860	A	20060720	MX 2006-PA860	20060123 <--
NO 2006000870	A	20060407	NO 2006-870	20060222 <--
PRIORITY APPLN. INFO.:			US 2003-489102P	P 20030723 <--
			US 2004-540326P	P 20040202
			WO 2004-US23500	W 20040722

OTHER SOURCE(S): CASREACT 142:197889

GI



I

AB Title compound I is prepared I and salts thereof is prepared in several steps from 3-fluoro-4-nitrophenol, 4-chloro-N-methylpyridine-2-carboxamide and 4-chloro-3-(trifluoromethyl)phenylisocyanate. I inhibits PDGFR tyrosine kinase with IC50 = 83 nM. I is useful for the treatment of, e.g., inflammation and as an antiproliferative agent.

L12 ANSWER 12 OF 58 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:14184 CAPLUS

DOCUMENT NUMBER: 142:120497

TITLE: Combination liposomal formulations comprising phospholipids

INVENTOR(S): Jamil, Haris; Ahmad, Imran; Ahmad, Zafeer; Anyarambhatla, Gopal

PATENT ASSIGNEE(S): Neopharm, Inc., USA

SOURCE: PCT Int. Appl., 39 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005000266	A2	20050106	WO 2004-US16413	20040522 <--
WO 2005000266	A3	20050217		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1643971	A2	20060412	EP 2004-753271	20040522 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
US 2006165744	A1	20060727	US 2006-558159	20060208 <--
PRIORITY APPLN. INFO.:			US 2003-472664P	P 20030522 <--
			US 2003-495260P	P 20030813 <--
			WO. 2004-US16413	W 20040522

AB The present invention provides a composition comprising a physiologically acceptable carrier and two or more agents encapsulated in a liposome, wherein the combination of the two or more agents possess the following properties: (1) cytotoxicity to tumor cells, (2) nutritional properties, (3) use in application to nails, hair, skin or lips, or (4) activity against parasites and insects. The invention also provides a method of making such a composition. The invention further provides a method of treating cancer when the combination of the two or more agents is cytotoxic to tumor

cells. For example, an initial formulation of liposome-encapsulated paclitaxel (LEP) was prepared containing phosphatidylcholine, cholesterol and cardiolipin. Sucrose and tocopherol were added to the formulation as stabilizers in order to form a sterilized lyophilized cake. Either doxorubicin (0.5 to 1.5 mg/mL) or mitoxantrone (0.5 to 1.5 mg/mL) was dissolved in water, and the solution was employed to reconstitute the lyophilized LEP cakes. The drug to lipid ratio varied from 1:120 to 1:24 (weight/weight) for doxorubicin and 1:120 to 1:24 (weight/weight) for mitoxantrone.

The reconstitution of the LEP cake with doxorubicin or mitoxantrone solution resulted in entrapment of either of the additive drugs (doxorubicin or mitoxantrone) into the liposomal formulation of paclitaxel (LEP). Moreover, 78 to 100% of the additive drug was entrapped into the LEP at a drug to lipid ratio of 1:120 to 1:15 for mitoxantrone and 1:120 to 1:24 for doxorubicin. Presence of an addnl. drug, doxorubicin or mitoxantrone, did not alter entrapment efficiency of paclitaxel in liposomes, size or stability of liposomes. Paclitaxel content remained intact after entrapping mitoxantrone or doxorubicin. This suggested that both drugs can coexist in a single delivery system without compromising size, entrapment efficiency or stability of the liposomal formulation.

L12 ANSWER 13 OF 58 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:934484 CAPLUS

DOCUMENT NUMBER: 141:409779

TITLE: Polyvalent protein complexes including trivalent bispecific chimeric antibodies and conjugates for diagnosis and treatment of cancer, infection, cardiological disorder and autoimmune disease

INVENTOR(S): Rossi, Edmund A.; Chang, Chien-Hsing; McBride, William J.

PATENT ASSIGNEE(S): IBC Pharmaceuticals, USA; Immunomedics, Inc

SOURCE: PCT Int. Appl., 148 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004094613	A2	20041104	WO 2004-US12662	20040422 <--
WO 2004094613	A3	20051222		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004232928	A1	20041104	AU 2004-232928	20040422 <--
CA 2522819	A1	20041104	CA 2004-2522819	20040422 <--
US 2005003403	A1	20050106	US 2004-829388	20040422 <--
EP 1618181	A2	20060125	EP 2004-750590	20040422 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
JP 2006526408	T	20061124	JP 2006-513283	20040422 <--
PRIORITY APPLN. INFO.:			US 2003-464532P	P 20030422 <--
			US 2003-525391P	P 20031124 <--
			WO 2004-US12662	W 20040422
AB	The invention provides for a polyvalent protein complex (PPC) comprising			

two polypeptide chains generally arranged laterally to one another. Each polypeptide chain typically comprises 3 or 4 'v-regions', which comprise amino acid sequences capable of forming an antigen binding site when matched with a corresponding v-region on the opposite polypeptide chain. Up to about 6 'v-regions' can be used on each polypeptide, chain. The v-regions of each polypeptide chain are connected linearly to one another and may be connected by interspersed linking regions. When arranged in the form of the PPC, the v-regions on each polypeptide chain form individual antigen binding sites.

L12 ANSWER 14 OF 58 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:780510 CAPLUS  
DOCUMENT NUMBER: 141:277486  
TITLE: A preparation of 7-aminoisoindolone derivatives  
INVENTOR(S): Man, Hon-Wah; Muller, George W.; Zhang, Weihong  
PATENT ASSIGNEE(S): Celgene Corporation, USA  
SOURCE: PCT Int. Appl., 109 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004080423	A2	20040923	WO 2004-US7743	20040312 <--
WO 2004080423	A3	20041104		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004220457	A1	20040923	AU 2004-220457	20040312 <--
CA 2518584	A1	20040923	CA 2004-2518584	20040312 <--
US 2004254214	A1	20041216	US 2004-798317	20040312 <--
US 7034052	B2	20060425		
EP 1605896	A2	20051221	EP 2004-720448	20040312 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
BR 2004008223	A	20060301	BR 2004-8223	20040312 <--
CN 1784382	A	20060607	CN 2004-80012360	20040312 <--
JP 2006519851	T	20060831	JP 2006-507155	20040312 <--
US 2006058362	A1	20060316	US 2005-250408	20051017 <--
US 7256210	B2	20070814		
PRIORITY APPLN. INFO.:			US 2003-454155P	P 20030312 <--
			US 2004-798317	A3 20040312
			WO 2004-US7743	W 20040312
OTHER SOURCE(S):			MARPAT 141:277486	
GI				

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The invention relates to a preparation of 7-aminoisoindole derivs. of formula I [wherein: Y is C(O), CH<sub>2</sub>, CH<sub>2</sub>C(O), or SO<sub>2</sub>; X is H; Z is -alkyl-CO<sub>2</sub>H, alkyl, -alkyl-OH, or -alkyl-NH<sub>2</sub>, etc.; R<sub>1</sub> and R<sub>2</sub> are independently

selected from (cyclo)alkyl or -alkyl-cycloalkyl], useful for treatment, prevention or management of cancer, inflammatory bowel disease, and myelodysplastic syndrome, etc. (no biol. data). For instance, isoindole derivative II was prepared via heterocyclization of aminopropanol derivative III and benzoic acid derivative IV with a yield of 64% (example 1).

L12 ANSWER 15 OF 58 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:780509 CAPLUS

DOCUMENT NUMBER: 141:295861

TITLE: A preparation of novel isoindolone derivatives, useful as PDE4 inhibitors

INVENTOR(S): Man, Hon-Wah; Muller, George W.

PATENT ASSIGNEE(S): Celgene Corporation, USA

SOURCE: PCT Int. Appl., 82 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004080422	A2	20040923	WO 2004-US7742	20040312 <--
WO 2004080422	A3	20041028		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004220456	A1	20040923	AU 2004-220456	20040312 <--
CA 2518513	A1	20040923	CA 2004-2518513	20040312 <--
US 2004259873	A1	20041223	US 2004-798372	20040312 <--
US 6911464	B2	20050628		
EP 1606256	A2	20051221	EP 2004-720480	20040312 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK			
BR 2004008220	A	20060214	BR 2004-8220	20040312 <--
CN 1784383	A	20060607	CN 2004-80012381	20040312 <--
JP 2006519850	T	20060831	JP 2006-507154	20040312 <--
US 2005203090	A1	20050915	US 2005-124280	20050509 <--
PRIORITY APPLN. INFO.:			US 2003-454149P	P 20030312 <--
			US 2004-798372	A3 20040312
			WO 2004-US7742	W 20040312
OTHER SOURCE(S):	MARPAT 141:295861			
GI				

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The invention relates to a preparation of novel isoindolone derivs. of formula I [wherein: Y is C(O), CH<sub>2</sub>, CH<sub>2</sub>C(O), or SO<sub>2</sub>; R<sub>1</sub> and R<sub>2</sub> are independently selected from (cyclo)alkyl, CF<sub>2</sub>H, CF<sub>3</sub>, or CH<sub>2</sub>CHF<sub>2</sub>, etc.; Z<sub>1</sub> is H, alkyl, NH<sub>2</sub>, or NH<sub>2</sub>, etc.; Z<sub>2</sub> is H or CHO, -C(O)-alkyl, or -C(O)Ph, etc.; X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub>, and X<sub>4</sub> are independently selected from H, halogen, NO<sub>2</sub>, CF<sub>3</sub>, alkyl, or alkylimidazolyl, etc.; R<sub>3</sub> and R<sub>4</sub> are independently H or alkyl], useful for



treatment or prevention of various diseases and disorders, for example, diseases associated with PDE4 (no biol. data). For instance, isoindolone derivative II was prepared via amination of N-(hydroxypropyl)isoindolone derivative

III by N,O-(tert-butoxycarbonyl)hydroxylamine with a yield of 78%.

L12 ANSWER 16 OF 58 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:739864 CAPLUS

DOCUMENT NUMBER: 141:254534

TITLE: Human p53 deletion mutant proteins and therapeutic use in cancer therapy

INVENTOR(S): Kline, Kimberly; Sanders, Bob G.; Yu, Weiping

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 25 pp., Cont.-in-part of U.S. Ser. No. 444,287..

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004175813	A1	20040909	US 2003-696255	20031029 <--
US 2004034198	A1	20040219	US 2003-444287	20030523 <--
WO 2005040356	A2	20050506	WO 2004-US35589	20041027 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:  
US 2002-383034P P 20020524 <--  
US 2003-444287 A2 20030523 <--  
US 2003-696255 A 20031029 <--

AB The present invention provides expression vectors that encode mutant p53 proteins (p53  $\Delta$ 126-132 mutant and p53  $\Delta$ 126-132 +  $\Delta$ 367-393 double mutant), host cells that contain these expression vectors, as well as methods of using the mutant p53 proteins disclosed herein to increase a cell's sensitivity to apoptotic inducing agent or inhibit tumor cell growth. The mutant p53 exhibits high cellular retention and is capable of rendering tumor cells sensitive to apoptotic inducing agents such as  $\gamma$ -irradiation or chemotherapeutic agents. The mutant p53 protein can be delivered sep. or in combination with apoptotic inducing agents via aerosol liposome/transfection/infection methods to treat cellular proliferative diseases and disorders in humans and animals.

L12 ANSWER 17 OF 58 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:634029 CAPLUS

DOCUMENT NUMBER: 141:162331

TITLE: Therapeutic use of siRNA inhibition of cell adhesion molecule ICAM-1 for treating angiogenic diseases

INVENTOR(S): Reich, Samuel Jotham; Tolentino, Michael J.

PATENT ASSIGNEE(S): The Trustees of the University of Pennsylvania, USA

SOURCE: PCT Int. Appl., 71 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

## PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004065546	A2	20040805	WO 2004-US1166	20040116 <--
WO 2004065546	A3	20060323		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
AU 2004205895	A1	20040805	AU 2004-205895	20040116 <--
CA 2513623	A1	20040805	CA 2004-2513623	20040116 <--
US 2004220129	A1	20041104	US 2004-759878	20040116 <--
EP 1604010	A2	20051214	EP 2004-702982	20040116 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

PRIORITY APPLN. INFO.: US 2003-440579P P 20030116 <--  
WO 2004-US1166 W 20040116

AB RNA interference using small interfering RNAs which are specific for the ICAM-1 gene inhibits expression of this gene. Diseases which involve ICAM-1-mediated cell adhesion, such as inflammatory and autoimmune diseases, diabetic retinopathy and other complications arising from type I diabetes, age related macular degeneration and many types of cancer, can be treated by administering the small interfering RNAs.

L12 ANSWER 18 OF 58 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:633318 CAPLUS

DOCUMENT NUMBER: 141:152227

TITLE: Human tocopherol associated protein 38 (TAP-38), TAP-46 and TAP-46 deletion mutants, their sequences, recombinant production and use along with drugs in treatment of cell proliferative disorders

INVENTOR(S): Sanders, Bob G.; Kline, Kimberly; Yu, Weiping; Liu, Hui; Hantash, Feras M.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 36 pp., Cont.-in-part of U.S. Pat. Appl. 2004 23,915:

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004152883	A1	20040805	US 2003-696699	20031029 <--
US 2004023915	A1	20040205	US 2003-419629	20030421 <--
US 7045324	B2	20060516		
WO 2005044987	A2	20050519	WO 2004-US35646	20041027 <--
WO 2005044987	A3	20070208		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,			

EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,  
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
SN, TD, TG

PRIORITY APPLN. INFO.:

US 2002-373870P P 20020419 <--  
US 2003-419629 A2 20030421 <--  
US 2003-696699 A 20031029 <--

AB The invention provides cDNA mols. encoding human tocopherol associated protein 38 (TAP-38) and tocopherol associated protein 46 (TAP-46), vectors containing said TAP-38 and TAP-46 proteins, and use of vectors in treatment of cell proliferative diseases. The invention also provides cDNA mols. encoding C-terminal mutants of TAP-46, designated TAP-882, TAP-681, TAP-456, and vectors encoding said proteins. The invention relates that said vectors may be administered in the form of an aerosolized liposome, and administered along with an anti-cancer drug. The invention further provides the cDNA sequences of TAP-38 and TAP-46 mutants, and amino acid sequences of TAP-38, TAP-46 and TAP-46 mutants. Finally, the invention provides TAP-38 and TAP-46 mutants tagged with green fluorescent protein, HA, His or GST, and antibodies directed against TAP-38. The invention discussed that TAP-38, which shares homol. with the previously identified TAP-46, enhances the apoptotic inducing properties of tocopherol based compds., and blockage of TAP-38 or TAP-46 reduces the effectiveness of tocopherol based compds. The invention specifically demonstrated that transfection of MDA-MB-435 human breast cancer cells with either TAP-46 or TAP-38 enhanced the ability of 2,5,7,8-tetramethyl-(2R-(4R,8R,12-trimethyltridecyl) chroman-6-yloxy) acetic acid to induce apoptosis.

L12 ANSWER 19 OF 58 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:589381 CAPLUS

DOCUMENT NUMBER: 141:140314

TITLE: Preparation of 2-(fluoroalkoxyphenylalkyl)-1,3-dihydroisoindolones as PDE4, TNF- $\alpha$ , and/or MMP inhibitors

INVENTOR(S): Muller, George W.; Man, Hon-Wah; Zhang, Weihong

PATENT ASSIGNEE(S): Celgene Corporation, USA

SOURCE: PCT Int. Appl., 98 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004060313	A2	20040722	WO 2003-US41568	20031229 <--
WO 2004060313	A3	20050915		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2511843	A1	20040722	CA 2003-2511843	20031229 <--
AU 2003303511	A1	20040729	AU 2003-303511	20031229 <--
US 2004204448	A1	20041014	US 2003-748085	20031229 <--
US 7173058	B2	20070206		
EP 1587474	A2	20051026	EP 2003-808605	20031229 <--
EP 1587474	A3	20051102		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2003017885	A	20051206	BR 2003-17885	20031229 <--

JP 2006515310	T	20060525	JP 2004-565816	20031229 <--
CN 1802353	A	20060712	CN 2003-80109907	20031229 <--
MX 2005PA06998	A	20050818	MX 2005-PA6998	20050627 <--
US 2007072902	A1	20070329	US 2006-601355	20061116 <--
PRIORITY APPLN. INFO.:			US 2002-436975P	P 20021230 <--
			US 2003-748085	A3 20031229 <--
			WO 2003-US41568	W 20031229 <--

OTHER SOURCE(S): MARPAT 141:140314  
GI



I



II

AB Title compds. I [wherein X1-X4 = independently H, halo, NO<sub>2</sub>, NH<sub>2</sub>, CF<sub>3</sub>, alkyl, cycloalkyl(alkyl), NR<sub>7</sub>R<sub>8</sub>-(alkyl), R<sub>8</sub>CONH-(alkyl), NR<sub>7</sub>R<sub>8</sub>CONH-(alkyl), R<sub>8</sub>OCNH-(alkyl), R<sub>8</sub>O-(alkyl), imidazolyl(alkyl), pyrrolyl(alkyl), oxadiazolyl(alkyl), triazolyl(alkyl); or X1 and X2 or X2 and X3 or X3 and X4 may be taken together to form a (hetero)cycloalkyl ring; Y = CO, CH<sub>2</sub>, CH<sub>2</sub>CO, COCH<sub>2</sub>, SO<sub>2</sub>; Z = H, COR<sub>3</sub>, alkylsulfonyl(alkyl), alkyl, CH<sub>2</sub>OH, alkoxyethyl, CN; R<sub>1</sub> and R<sub>2</sub> = independently CHF<sub>2</sub>, alkyl, cycloalkyl(alkyl); at least one of R<sub>1</sub> and R<sub>2</sub> = CHF<sub>2</sub>; R<sub>3</sub> = NR<sub>4</sub>R<sub>5</sub>, alkyl, OH, alkoxy, (un)substituted Ph, PhCH<sub>2</sub>; R<sub>4</sub> and R<sub>5</sub> = independently H, alkyl, OH, OCOR<sub>6</sub>; R<sub>6</sub> = alkyl(amino), Ph, PhCH<sub>2</sub>, aryl; R<sub>7</sub> and R<sub>8</sub> = independently H, alkyl, cycloalkyl(alkyl), NR<sub>7</sub>R<sub>8</sub>-alkyl, R<sub>8</sub>O-alkyl, Ph, PhCH<sub>2</sub>, aryl; or pharmaceutically acceptable salts, hydrates, solvates, clathrates, stereoisomers, and prodrugs thereof] were prepared. For example, alkylation of 3,4-dihydroxybenzaldehyde with chlorodifluoromethane in the presence of K<sub>2</sub>CO<sub>3</sub> in DMF gave 4-difluoromethoxy-3-hydroxybenzaldehyde (15%), which was further alkylated with bromomethylcyclopropane under the same conditions to afford 3-cyclopropylmethoxy-4-difluoromethoxybenzaldehyde (100%). Reaction of the benzaldehyde with ammonium acetate in 95% EtOH, followed by addition of malonic acid provided 3-amino-3-(3-cyclopropylmethoxy-4-difluoromethoxyphenyl)propionic acid (52%). Condensation of the amine with 3-acetamidophthalic anhydride using sodium acetate in AcOH yielded the isoindole-1-one II (85%). I and their pharmaceutical compns., optionally in combination with another therapeutic agent, are useful for the treatment or prevention of diseases associated with phosphodiesterase 4 (PDE4) inhibition, abnormal tumor necrosis factor  $\alpha$  (TNF- $\alpha$ ) levels, and/or matrix metalloproteinase (MMP) inhibition, such as myelodysplastic syndrome, myeloproliferative disease, complex regional pain syndrome, cancer, inflammatory diseases, and autoimmune diseases (no

data).

L12 ANSWER 20 OF 58 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2004:143127 CAPLUS  
DOCUMENT NUMBER: 140:193099  
TITLE: Heterocyclic compound proteasome inhibitors,  
pharmaceutical compositions, and therapeutic use  
INVENTOR(S): Burrill, Leland C., III; Mendonca, Rohan V.; Palmer,  
James T.; Rydzewski, Robert M.  
PATENT ASSIGNEE(S): Axys Pharmaceuticals, USA  
SOURCE: PCT Int. Appl., 59 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004014882	A2	20040219	WO 2003-US24960	20030808 <--
WO 2004014882	A3	20040805		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003255240	A1	20040225	AU 2003-255240	20030808 <--
PRIORITY APPLN. INFO.:			US 2002-402183P	P 20020809 <--
			WO 2003-US24960	W 20030808 <--

OTHER SOURCE(S): MARPAT 140:193099

AB The invention discloses heterocyclic compds. that are proteasome inhibitors, pharmaceutical compns. comprising such compds., and methods of treating diseases mediated by unregulated proteasome activity. Compound preparation is included.

=> d 21-20 L12 ibib abs

'21-20' IS NOT A VALID FORMAT

In a multifile environment, a format can only be used if it is valid in at least one of the files. Refer to file specific help messages or the STNGUIDE file for information on formats available in individual files.

REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):end

=> d 21-30 L12 ibib abs

L12 ANSWER 21 OF 58 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2003:989927 CAPLUS  
DOCUMENT NUMBER: 140:19891  
TITLE: Compositions for treatment of diseases arising from secretion of mast cell biochemicals  
INVENTOR(S): Theoharides, Theoharis C.  
PATENT ASSIGNEE(S): USA  
SOURCE: U.S. Pat. Appl. Publ., 8 pp., Cont.-in-part of Ser. No. US 2001-773576, filed on 2 Feb 2001  
whichDivision of  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 7

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003232100	A1	20031218	US 2003-439301	20030516 <--
US 6689748	B1	20040210	US 1998-56707	19980408 <--
PRIORITY APPLN. INFO.:			US 1998-56707	A3 19980408 <--
			US 2001-773576	A2 20010202 <--

AB Compns. for treatment of diseases arising from products secreted by activated tissue mast cells, composed of, as active ingredients, unprocessed olive kernel (pit) extract that increases absorption of these compns. in various routes of administration, and one or more of a heavily sulfated, non-bovine proteoglycan such as shark cartilage chondroitin sulfate C, a hexosamine sulfate such as D-glucosamine sulfate, a flavonoid such as quercetin, S-adenosylmethionine, a histamine-1 receptor antagonist, a histamine-3 receptor agonist, a CRH antagonist, caffeine, fragments of myelin basic protein, rutin, polyunsatd. fatty acids, Bitter Willow Extract and a polyamine.

L12 ANSWER 22 OF 58 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:951051 CAPLUS

DOCUMENT NUMBER: 140:24698

TITLE: Human mutant p53 ( $\Delta$ 126-132) identified in c-Jun over-expressing MCF-7 cell and their therapeutic uses

INVENTOR(S): Kline, Kimberly; Sanders, Bob G.; Yu, Weiping

PATENT ASSIGNEE(S): Research Development Foundation, USA

SOURCE: PCT Int. Appl., 42 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003099850	A2	20031204	WO 2003-US16492	20030523 <--
WO 2003099850	A3	20050203		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003249644	A1	20031212	AU 2003-249644	20030523 <--
PRIORITY APPLN. INFO.:			US 2002-383034P	P 20020524 <--
			WO 2003-US16492	W 20030523 <--

AB A p53 cDNA with a 21 nucleotide base deletion that codes for a seven amino acid deleted p53 protein was disclosed herein. The mutant p53 exhibits high cellular retention and is capable of rendering tumor cells sensitive to apoptotic inducing agents such as  $\gamma$ -irradiation or chemotherapeutic agents. The mutant p53 protein can be delivered sep. or in combination with apoptotic inducing agents via aerosol liposome /transfection/infection methods to treat cellular proliferative diseases and disorders in humans and animals. Thus, the present invention claim that expression of mutant p53 by tumor cells enhances the effects of apoptotic inducing agents. MCF-7 c-Jun over-expressing cells constitutively expressed high levels of p53 but reduced levels of Bcl-2 and Bcl-XL compared to parental vector control cells. Blockage of p53 using p53 antisense oligomers in c-Jun over-expressing cells resulted in

up-regulation of Bcl-2 protein, showing that p53 is regulating the expression of Bcl-2 protein. Furthermore, cells treated with p53 antisense oligomers were resistant to apoptotic inducing agents, and exhibited reduced levels of p53 protein and enhanced levels of Bcl-2 protein, indicating that p53-mediated reduced levels of Bcl-2 are associated with increased sensitivity of these cells to apoptotic agents.

L12 ANSWER 23 OF 58 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:856050 CAPLUS  
DOCUMENT NUMBER: 139:346800  
TITLE: Protein and cDNA sequences of human tocopherol associated protein TAP-38 and TAP-46, and therapeutic use  
INVENTOR(S): Sanders, Bob G.; Kline, Kimberly; Yu, Weiping; Hantash, Feras; Liu, Hui  
PATENT ASSIGNEE(S): Research Development Foundation, USA  
SOURCE: PCT Int. Appl., 63 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003089613	A2	20031030	WO 2003-US12238	20030421 <--
WO 2003089613	A3	20050203		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG.				
CA 2482909	A1	20031030	CA 2003-2482909	20030421 <--
AU 2003231010	A1	20031103	AU 2003-231010	20030421 <--
EP 1520014	A2	20050406	EP 2003-724131	20030421 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006506951	T	20060302	JP 2003-586326	20030421 <--
PRIORITY APPLN. INFO.: US 2002-373870P P 20020419 <--				
WO 2003-US12238 W 20030421 <--				
AB The present invention provides a novel tocopherol associated protein (TAP-38) DNA/protein with a (76) nucleotide base deletion resulting in a (25) amino acid deletion, followed by (90) novel nucleotides that code for (30) novel amino acids that are not expressed by TAP-46. The present invention provides data showing that TAP-38 enhances the apoptotic inducing properties of tocopherol based compds., and blockage of TAP reduces the effectiveness of tocopherol based compds. Thus, the present invention claim that expression of TAP-38 by tumor cells enhances the apoptotic inducing properties of tocopherol based compds. The present invention provides aerosol liposome/transfection/infection methods for delivery of TAP-38 and TAP-46 cDNA plasmids sep. and in combination with tocopherol based apoptotic inducing agents as well as with other chemotherapeutic agents as a method for treatment and prevention of cellular proliferative diseases and disorders.				

L12 ANSWER 24 OF 58 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:833884 CAPLUS  
DOCUMENT NUMBER: 139:317425  
TITLE: Smac-peptides as therapeutics against cancer and autoimmune diseases by sensitizing for TRAIL- or

INVENTOR(S): anticancer drug-induced apoptosis  
 Debatin, Klaus Michael; Fulda, Simone  
 PATENT ASSIGNEE(S): Deutsches Krebsforschungszentrum Stiftung des  
 Oeffentlichen Rechts, Germany  
 SOURCE: Eur. Pat. Appl., 19 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1354952	A1	20031022	EP 2002-8199	20020417 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EP 1354953	A1	20031022	EP 2002-15499	20020712 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
WO 2003086470	A2	20031023	WO 2003-EP4039	20030417 <--
WO 2003086470	A3	20040506		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003236211	A1	20031027	AU 2003-236211	20030417 <--
EP 1495124	A2	20050112	EP 2003-722503	20030417 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005536457	T	20051202	JP 2003-583486	20030417 <--
US 2005222387	A1	20051006	US 2005-511037	20050119 <--
PRIORITY APPLN. INFO.:				
			EP 2002-8199	A 20020417 <--
			EP 2002-15499	A 20020712 <--
			WO 2003-EP4039	W 20030417 <--

AB The invention is directed to the use of Smac to sensitize different tumors and self-reactive immune cells to various pro-apoptotic stimuli, in that the cells subsequently undergo apoptosis. Therefore, Smac can be used as a compound for the manufacture of a medicament for the treatment of cancer and autoimmune diseases. Sensitization of the cells is achieved either by applying a cell-permeable form of Smac combined with known anticancer agents or by overexpression of the protein. It is an object of the invention to provide a new method in cancer and autoimmune disease therapy by using Smac agonists for apoptosis regulation. Thus, Smac agonists represent novel promising cancer and autoimmune disease therapeutics to potentiate the efficacy of cytotoxic therapies even in resistant tumors and immune cells. In particular, overexpression of full-length Smac protein potentiated TRAIL-induced apoptosis and also markedly increased apoptosis induced by anti-CD95 antibody or cytotoxic drugs in transfected SHEP neuroblastoma cells. The overexpression of Smac is shown to promote apoptosis through antagonizing the inhibition of XIAP of both distal and proximal events in the caspase cascade. The cytosolic Smac, with the deletion of transit peptide for mitochondria (N-terminal 55 AA), bypasses Bcl-2 inhibition in several cell types in response to different pro-apoptotic stimuli. The cell permeable Smac peptide (4 N-terminal IAP-interacting plus 3 addition following residues linked to TAT transduction domain) can facilitate intracellular delivery of Smac peptide and sensitize several resistant cell lines with defects in apoptosis signaling for treatment with TRAIL or doxorubicin. Expression of a cytosolic active



form of Smac or cell-permeable Smac peptides bypassed the Bcl-2 block, which prevented the release of Smac from mitochondria, and also sensitized resistant neuroblastoma or melanoma cells and patient-derived primary neuroblastoma cells ex vivo. Thus, Smac agonists represent novel promising cancer therapeutics to potentiate the efficacy of cytotoxic therapies. Smac peptides is shown to enhance the antitumor effect of TRAIL in glioblastoma in mouse glioblastoma model and induce eradication of tumors.

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 25 OF 58 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:678486 CAPLUS

DOCUMENT NUMBER: 139:191463

TITLE: Glucocorticoid blocking agents for increasing blood-brain barrier permeability

INVENTOR(S): Schatzberg, Alan F.; Lindley, Steven; Belanoff, Joseph K.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 15 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003162695	A1	20030828	US 2002-87227	20020227 <--
US 2005124533	A1	20050609	US 2004-949739	20040924 <--
PRIORITY APPLN. INFO.:			US 2002-87227	B1 20020227 <--

AB Glucocorticoid blockers, including glucocorticoid receptor antagonists, are effective to prevent glucocorticoid-induced decrease in permeability of the blood-brain barrier and to increase the permeability of the blood-brain barrier. Administration of glucocorticoid blockers, including glucocorticoid receptor antagonists, concomitant with administration of drugs for treating diseases of the central nervous system increases delivery of such drugs into the central nervous system. Corticosterone decreased blood-brain barrier permeability of haloperidol and clozapine in rats.

L12 ANSWER 26 OF 58 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:656581 CAPLUS

DOCUMENT NUMBER: 139:197370

TITLE: Preparation of aryl ureas containing pyridine, quinoline and isoquinoline N-oxide functionality as kinase inhibitors

INVENTOR(S): Dumas, Jacques; Scott, William J.; Riedl, Bernd

PATENT ASSIGNEE(S): Bayer Corporation, USA

SOURCE: PCT Int. Appl., 67 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003068229	A1	20030821	WO 2003-US4110	20030211 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,			

UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,  
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,  
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003209119 A1 20030904 AU 2003-209119 20030211 <--  
 US 2003216396 A1 20031120 US 2003-361850 20030211 <--  
 PRIORITY APPLN. INFO.: US 2002-354935P P 20020211 <--  
 WO 2003-US4110 W 20030211 <--  
 OTHER SOURCE(S): MARPAT 139:197370  
 GI



AB The title ureas containing a pyridine, quinoline, or isoquinoline functionality which is oxidized at the nitrogen heteroatom MLBNHCONHA [A = (un)substituted Ph, naphthyl, 5-6 membered monocyclic heteroaryl, 8-10 membered bicyclic heteroaryl; B = (un)substituted phenylene, naphthylene, 5-6 membered monocyclic heteroarylene, 8-10 membered bicyclic heteroarylene; L = (CH<sub>2</sub>)<sub>m</sub>O(CH<sub>2</sub>)<sub>l</sub>, (CH<sub>2</sub>)<sub>m</sub>(CH<sub>2</sub>)<sub>l</sub>, (CH<sub>2</sub>)<sub>m</sub>CO(CH<sub>2</sub>)<sub>l</sub>, etc.; m, l = 0-4; M = (un)substituted pyridine-1-oxide, quinoline-1-oxide, isoquinoline-1-oxide; with the provisos] which are useful in the treatment of (i) raf mediated diseases, for example, cancer, (ii) p38 mediated diseases such as inflammation and osteoporosis, and (iii) VEGF mediated diseases such as angiogenesis disorders, were claimed. Preparation of two ureas such as I [R = H, Me] which are not compds. of the invention, and have been distinguished from the compds. of the invention by a proviso, was described. Pharmaceutical composition comprising the title ureas was claimed.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 27 OF 58 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:356569 CAPLUS

DOCUMENT NUMBER: 138:367591

TITLE: Anti-TRAIL receptor antibodies and other therapeutic agents for treating neoplastic, inflammatory and autoimmune diseases

INVENTOR(S): Zhou, Tong; Ichikawa, Kimihisa; Kimberly, Robert P.; Koopman, William J.; Oshumi, Jun; Lobuglio, Albert F.; Buchsbaum, Donald J.

PATENT ASSIGNEE(S): UAB Research Foundation, USA

SOURCE: PCT Int. Appl., 274 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003038043	A2	20030508	WO 2002-US34420	20021025 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,			

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,  
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,  
 UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,  
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,  
 CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2465314 A1 20030508 CA 2002-2465314 20021025 <--  
 US 2003133932 A1 20030717 US 2002-281479 20021025 <--  
 EP 1506285 A2 20050216 EP 2002-795556 20021025 <--  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK  
 CN 1630516 A 20050622 CN 2002-826532 20021025 <--  
 JP 2005519871 T 20050707 JP 2003-540308 20021025 <--  
 HU 200600602 A2 20061028 HU 2006-602 20021025 <--  
 BR 2002013846 A 20061121 BR 2002-13846 20021025 <--  
 MX 2004PA04184 A 20050125 MX 2004-PA4184 20040430 <--  
 IN 2004DN01205 A 20061208 IN 2004-DN1205 20040505 <--  
 NO 2004002266 A 20040723 NO 2004-2266 20040601 <--  
 PRIORITY APPLN. INFO.: US 2001-346402P P 20011101 <--  
 US 2002-391478P P 20020624 <--  
 WO 2002-US34420 W 20021025 <--

AB An antibody of the invention interacts with tumor necrosis factor-related apoptosis-inducing ligand receptor such as human DR5 or DR4 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Methods and uses for the antibodies, optionally in combination with various therapeutic agents, are detailed, including treatment of apoptosis-related disease and treatment of dysregulated cell growth, such as cancer, inflammation and autoimmune diseases.

L12 ANSWER 28 OF 58 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:334910 CAPLUS

DOCUMENT NUMBER: 138:331734

TITLE: Drugs comprising combination of triazaspiro[5.5]undecane derivative with cytochrome p450 isozyme 3a4 inhibitor and/or P-glycoprotein inhibitor

INVENTOR(S): Imawaka, Haruo; Shibayama, Shiro; Takaoka, Yoshikazu

PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 183 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003035074	A1	20030501	WO 2002-JP2552	20020318 <--
W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW	
RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
CA 2461545	A1	20030501	CA 2002-2461545	20020318 <--
AU 2002238945	A1	20030506	AU 2002-238945	20020318 <--
EP 1438962	A1	20040721	EP 2002-705299	20020318 <--
R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,	

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

CN 1571671	A	20050126	CN 2002-820391	20020318 <--
BR 2002013372	A	20050201	BR 2002-13372	20020318 <--
HU 200500028	A2	20050428	HU 2005-28	20020318 <--
NO 2004001618	A	20040722	NO 2004-1618	20040421 <--
MX 2004PA03816	A	20040730	MX 2004-PA3816	20040422 <--
ZA 2004003086	A	20050511	ZA 2004-3086	20040422 <--
PRIORITY APPLN. INFO.:			JP 2001-324435	A 20011023 <--
			WO 2002-JP2552	W 20020318 <--

OTHER SOURCE(S): MARPAT 138:331734

GI



AB Drugs comprising a combination of triazaspiro[5.5]undecane derivs. represented by the following general formula (I): I wherein each symbol is as will be defined hereinafter; quaternary ammonium salts thereof, N-oxides of the same or nontoxic salts of the same with at least one cytochrome P 450 isoenzyme 3A4 inhibitor and/or at least one P-glycoprotein inhibitor. The drugs comprising such a combination, wherein the bioavailability of the compds. represented by the general formula I is elevated, are efficaciously usable as oral preps. in treating various diseases.

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 29 OF 58 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:135495 CAPLUS

DOCUMENT NUMBER: 138:158771

TITLE: Therapy of proliferative disorders by direct irradiation of cell nuclei with tritiated nuclear targeting agents

INVENTOR(S): Gatenby, Robert A.

PATENT ASSIGNEE(S): Temple University-of the Commonwealth System of Higher Education, USA

SOURCE: PCT Int. Appl., 66 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001072203	A2	20011004	WO 2001-US8446	20010316 <--
WO 2001072203	A3	20021010		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN,			

GW, ML, MR, NE, SN, TD, TG  
 EP 1283674 A2 20030219 EP 2001-928305 20010316 <--  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR  
 US 2003125283 A1 20030703 US 2002-221969 20020916 <--  
 PRIORITY APPLN. INFO.: US 2000-192153P P 20000324 <--  
 US 2000-192671P P 20000328 <--  
 WO 2001-US8446 W 20010316 <--

AB The present invention provides methods of treating proliferative disorders in vivo by the direct administration of tritium to target cell nuclei. Tritium is administered to target cell nuclei by a tritiated nuclear targeting agent, which is directed to the target cell nucleus where it assoc. with the cell's DNA. The close association of the tritiated nuclear targeting agent with the target cell DNA allows the low-energy beta particle emitted by the tritium to damage to the target cell DNA and kill the cell. Tritiated nuclear targeting agents can also be delivered to the target cells by structures such as liposomes, micelles and microcapsules. Examples are provided on biodistribution, tumor uptake, and tumor cell killing by 3H-thymidine, and on the preparation of liposomal formulations of the tritiated c-myc oligonucleotide CAC GTT GAG GGG CAT. The liposomes are modified using an opsonization-inhibiting moiety such as PEG and/or by attachment of a targeting group such as an antibody.

L12 ANSWER 30 OF 58 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:960660 CAPLUS

DOCUMENT NUMBER: 138:19488

TITLE: Method and pharmaceutical compositions using anti-microtubule agents for treating multiple sclerosis and other inflammatory diseases

INVENTOR(S): Hunter, William L.

PATENT ASSIGNEE(S): Angiotech Pharmaceuticals, Inc., Can.

SOURCE: U.S., 180 pp., Cont.-in-part of U.S. Appl. 2002 37,919.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6495579	B1	20021217	US 1998-88546	19980601 <--
US 2002037919	A1	20020328	US 1997-980549	19971201 <--
US 6515016	B2	20030204		
EP 1070502	A2	20010124	EP 2000-123557	19971202 <--
EP 1070502	A3	20011017		
EP 1070502	B1	20030604		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1090637	A2	20010411	EP 2000-123537	19971202 <--
EP 1090637	A3	20010912		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1092433	A2	20010418	EP 2000-123534	19971202 <--
EP 1092433	A3	20010912		
EP 1092433	B1	20030806		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002226399	A	20020814	JP 2001-401899	19971202 <--
EP 1582210	A2	20051005	EP 2005-11601	19971202 <--
EP 1582210	A3	20051012		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CN 1679937	A	20051012	CN 2005-10054770	19971202 <--

CN 101011576 A 20070808 CN 2006-10099927 19971202 <--  
 WO 9962510 A2 19991209 WO 1999-CA464 19990601 <--  
 W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,  
 DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE,  
 KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW,  
 MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR,  
 TT, UA, UG, US, UZ, VN, YU, ZA, ZW  
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,  
 ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,  
 CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
 US 2002013298 A1 20020131 US 1999-368463 19990804 <--  
 US 2002183380 A1 20021205 US 2002-67467 20020205 <--  
 US 6689803 B2 20040210  
 US 2003157187 A1 20030821 US 2002-172737 20020613 <--  
 AU 2004200715 A1 20040318 AU 2004-200715 20040220 <--  
 US 2005249770 A1 20051110 US 2005-102587 20050408 <--  
 AU 2006220416 A1 20061026 AU 2006-220416 20060920  
 PRIORITY APPLN. INFO.: US 1996-32215P P 19961202 <--  
 US 1997-63087P P 19971024 <--  
 US 1997-980549 A2 19971201 <--  
 CN 1997-181581 A3 19971202 <--  
 CN 2005-10054770 A3 19971202 <--  
 EP 1997-945697 A3 19971202 <--  
 EP 2000-123537 A3 19971202 <--  
 JP 1998-524997 A3 19971202 <--  
 US 1998-88546 A 19980601 <--  
 US 1999-368463 B1 19990804 <--  
 US 1999-368871 A1 19990804 <--  
 AU 2001-48029 A3 20010525 <--  
 US 2002-172737 B1 20020613 <--  
 AU 2004-200715 A3 20040220  
 AB. Methods and compns. for treating or preventing inflammatory diseases, e.g.  
 psoriasis or multiple sclerosis, are provided,  
 comprising delivering to the site of inflammation an anti-microtubule  
 agent (e.g. paclitaxel), or analog or derivative thereof.  
 REFERENCE COUNT: 171 THERE ARE 171 CITED REFERENCES AVAILABLE FOR  
 THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
 FORMAT

=> d 31-40 L12 ibib abs

L12 ANSWER 31 OF 58 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2002:595351 CAPLUS  
 DOCUMENT NUMBER: 137:139376  
 TITLE: Non-cytolytic soluble factor from activated-expanded  
 CD4 cells  
 INVENTOR(S): Triozzi, Pierre L.; Ridihalgh, John L.; Bresler,  
 Herbert S.  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 62 pp.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002106375	A1	20020808	US 2000-727198	20001130 <--
US 6713054	B1	20040330	US 1998-167764	19981007 <--
WO 2002045201	A2	20020606	WO 2001-US45126	20011130 <--
WO 2002045201	A3	20031002		
W: AU, CA, CN, IL, JP, KR, RU				

RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,  
PT, SE, TR

PRIORITY APPLN. INFO.:

US 1997-943993 A 19971003 <--  
US 1998-167764 A 19981007 <--  
US 2000-246802P P 20001108 <--  
US 2000-727198 A 20001130 <--

AB A new factor, Factor C, is produced by the activated-expanded autologous cells of cancer patients, HIV-1 infected patients, chronic fatigue syndrome patients, healthy patients, etc. Factor C has a mol. weight of about 70,000 to 80,000 daltons, is heat stable, has an amino acid sequence that is absent from the National Center for Biotechnol. Information database, and whose amino acid sequence is not homologous to TNF family ligands. Factor C is derived from CD4 cells in a much greater quantity than from CD8 cells, and is derived from lymph cells in a greater quantity than from PBL cells. Factor C appears to inhibit transcription in virally-infected and tumor cells, and stimulates the proliferation of normal lymphocytes. Factor C exhibits synergistic activity with topoisomerase I, topoisomerase II, microtubule, and thymidylate synthetase active agents; is responsible for the synergistic induction of apoptosis; its effect is not secondary to enhanced cell cycling; inhibits the anti-apoptotic factor NF- $\kappa$ B implicated in chemoresistance; enhances uptake of doxorubicin in multi-drug resistant cells, increases covalent topoisomerase I-DNA complexes with topoisomerase I active drugs; and decreases thymidylate synthetase transcription in combination with 5-fluorouracil. Factor C with the hormonal agent, tamoxifen, is responsible for the synergistic induction of apoptosis and exhibits synergism in estrogen-receptor-neg. cell lines. Factor C, in combination with other agents, can be used to treat HIV infections, various viral infections, autoimmunity, cancer, bacterial infection, and immunosuppression.

L12 ANSWER 32 OF 58 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:521462 CAPLUS

DOCUMENT NUMBER: 137:88442

TITLE: Incensole and furanogermacrene and compounds in treatment for inhibiting neoplastic lesions and microorganisms

INVENTOR(S): Shanahan-Pendergast, Elisabeth

PATENT ASSIGNEE(S): Ire.

SOURCE: PCT Int. Appl., 68 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002053138	A2	20020711	WO 2002-IE1	20020102 <--
WO 2002053138	A3	20020919		
W: AE, AG, AT, AU, BB, BG, CA, CH, CN, CO, CU, CZ, LU, LV, MA, MD, UA, UG, US, VN, YU, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, AT, BE, CH, CY, DE, ES, FI, ML, MR, NE, SN, TD, TG				
AU 2002219472	A1	20020716	AU 2002-219472	20020102 <--
EP 1351678	A2	20031015	EP 2002-727007	20020102 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2004092583	A1	20040513	US 2004-250535	20040102 <--
PRIORITY APPLN. INFO.:				
			IE 2001-2	A 20010102 <--
			WO 2002-IE1	W 20020102 <--

OTHER SOURCE(S): MARPAT 137:88442


AB The invention discloses the use of incensole and/or furanogermacrene, derivs. metabolites and precursors thereof in the treatment of neoplasia,

particularly resistant neoplasia and immunodysregulatory disorders. These compds. can be administered alone or in combination with conventional chemotherapeutic, antiviral, antiparasite agents, radiation and/or surgery. Incensole and furanogermacren and their mixture showed antitumor activity against various human carcinomas and melanomas and antimicrobial activity against Staphylococcus aureus and Enterococcus faecalis.

L12 ANSWER 33 OF 58 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:449662 CAPLUS  
DOCUMENT NUMBER: 137:33310  
TITLE: Preparation of anilinopyrimidines as IKK inhibitors  
INVENTOR(S): Kois, Adam; MacFarlane, Karen J.; Satoh, Yoshitaka; Bhagwat, Shripad S.; Parnes, Jason S.; Palanki, Moorthy S. S.; Erdman, Paul E.  
PATENT ASSIGNEE(S): Signal Pharmaceuticals, Inc., USA  
SOURCE: PCT Int. Appl., 194 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002046171	A2	20020613	WO 2001-US46403	20011205 <--
WO 2002046171	A3	20030123		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003203926	A1	20031030	US 2001-4642	20011204 <--
US 7122544	B2	20061017		
CA 2431160	A1	20020613	CA 2001-2431160	20011205 <--
AU 2002020195	A5	20020618	AU 2002-20195	20011205 <--
EP 1349841	A2	20031008	EP 2001-999564	20011205 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004523497	T	20040805	JP 2002-547910	20011205 <--
US 2006030576	A1	20060209	US 2005-211383	20050824 <--
PRIORITY APPLN. INFO.:				
			US 2000-251816P	P 20001206 <--
			US 2001-4642	A1 20011204 <--
			WO 2001-US46403	W 20011205 <--
OTHER SOURCE(S): MARPAT 137:33310				
GI				



I

AB The title compds. [I; R1 = (un)substituted (hetero)aryl; R2 = H; R3 = H, alkyl; R4 = halo, OH, alkyl, alkoxy; R5, R6 = R8, (CH2)aCOR9, (CH2)aCO2R9, etc.; or NR5R6 = (un)substituted heterocycle; R8, R9 = H, alkyl, aryl,




etc.; a = 0-4] having activity as inhibitors of IKK, particularly IKK-2, were prepared E.g., a multi-step synthesis of I [R1 = 4-ClC6H4; R2-R6 = H] having an IC50 of  $\leq 1 \mu\text{M}$  in the IKK-2 enzyme assay, was given. Such compds. I have utility in the treatment of a wide range of conditions that are responsive to IKK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compns. containing one or more compds. of the above compds.

L12 ANSWER 34 OF 58 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:449661 CAPLUS  
DOCUMENT NUMBER: 137:33309  
TITLE: Preparation of anilinopyrimidines as JNK pathway inhibitors  
INVENTOR(S): Kois, Adam; MacFarlane, Karen J.; Satoh, Yoshitaka; Bhagwat, Shripad S.; Parnes, Jason S.; Palanki, Moorthy S. S.; Erdman, Paul E.  
PATENT ASSIGNEE(S): Signal Pharmaceuticals, Inc., USA  
SOURCE: PCT Int. Appl., 199 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002046170	A2	20020613	WO 2001-US46402	20011205 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2430966	A1	20020613	CA 2001-2430966	20011205 <--
AU 2002027214	A5	20020618	AU 2002-27214	20011205 <--
EP 1349840	A2	20031008	EP 2001-996103	20011205 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004534728	T	20041118	JP 2002-547909	20011205 <--
PRIORITY APPLN. INFO.:			US 2000-251904P	P 20001206 <--
			WO 2001-US46402	W 20011205 <--
OTHER SOURCE(S):			MARPAT 137:33309	
GI				



AB The title compds. [I; R1 = (un)substituted (hetero)aryl; R2 = H; R3 = H, alkyl; R4 = halo, OH, alkyl, alkoxy; R5, R6 = R8, (CH2)aCOR9, (CH2)aCO2R9, etc.; or NR5R6 = (un)substituted heterocycle; R8, R9 = H, alkyl, aryl, etc.; a = 0-4] having activity as inhibitors of the JNK pathway, were prepared E.g., a multi-step synthesis of I [R1 = 4-ClC6H4; R2-R6 = H] having an IC50 of  $\leq 10 \mu\text{M}$  in the JNK2 assay, was given. Such

comps. I have utility in the treatment of a wide range of conditions that are responsive to inhibition of the JNK pathway. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical comps. containing one or more comps. of the above comps.

L12 ANSWER 35 OF 58 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:884254 CAPLUS  
DOCUMENT NUMBER: 136:160858  
TITLE: Top 200 medicines: can new actions be discovered through computer-aided prediction?  
AUTHOR(S): Poroikov, V.; Akimov, D.; Shabelnikova, E.; Filimonov, D.  
CORPORATE SOURCE: Institute of Biomedical Chemistry of the Russian Academy of Medical Sciences, Moscow, 119832, Russia  
SOURCE: SAR and QSAR in Environmental Research (2001), 12(4), 327-344  
CODEN: SQERED; ISSN: 1062-936X  
PUBLISHER: Gordon & Breach Science Publishers  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB Computer-aided prediction of the biol. activity spectra by the program PASS was applied to a set of 130 pharmaceuticals from the list of the Top 200 medicines. The known pharmacol. effects were found in the predicted activity spectra in 93.2% of cases. Addnl., the probability of some supplementary effects was also predicted to be significant, including angiogenesis inhibition, bone formation stimulation, possible use in cognition disorders treatment, multiple sclerosis treatment, etc. These predictions, if confirmed exptl., may become a cause for a new application of pharmaceuticals from the Top 200 list. Most of known side and toxic effects were also predicted by PASS. PASS predictions at earlier R & D stages may thus provide a basis for finding new "leads" among already launched drugs and may help direct more attention to those particular effects of pharmaceuticals in clin. use which become apparent only in a small part of the population and require addnl. precautions.

REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 36 OF 58 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:246515 CAPLUS  
DOCUMENT NUMBER: 134:261267  
TITLE:  $\alpha$ -Sulfonylamino hydroxamic acid inhibitors of matrix metalloproteinases for the treatment of peripheral or central nervous system disorders  
INVENTOR(S): Sahagan, Barbara Gail; Villalobos, Anabella  
PATENT ASSIGNEE(S): Pfizer Products Inc., USA  
SOURCE: Eur. Pat. Appl., 26 pp.  
CODEN: EPXXDW  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
EP 1088550	A1	20010404	EP 2000-308442	20000927 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AU 782986	B2	20050915	AU 2000-61307	20000926 <--
US 6417229	B1	20020709	US 2000-671435	20000927 <--
ZA 2000005217	A	20020328	ZA 2000-5217	20000928 <--
CA 2321593	A1	20010401	CA 2000-2321593	20000929 <--
JP 2001097854	A	20010410	JP 2000-298071	20000929 <--
HU 200003863	A2	20011228	HU 2000-3863	20000929 <--

PRIORITY APPLN. INFO.: US 1999-157083P P 19991001 <--  
OTHER SOURCE(S): MARPAT 134:261267

AB A method is provided for using the title compds., pharmaceutically acceptable salts thereof, or pharmaceutical compns. thereof, in the treatment of a disease, condition or disorder of the peripheral or central nervous system, including but not limited to Alzheimer's disease, stroke/cerebral ischemia, head trauma, spinal cord injury, multiple sclerosis, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease, migraine, cerebral amyloid angiopathy, AIDS, age-related cognitive decline, mild cognitive impairment and prion diseases.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 37 OF 58 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1998:621122 CAPLUS

DOCUMENT NUMBER: 129:239917

TITLE: Oxyalkylene phosphate compounds and therapeutic uses thereof

INVENTOR(S): Nudelman, Abraham; Rephaeli, Ada

PATENT ASSIGNEE(S): Beacon Laboratories, L.L.C., USA

SOURCE: PCT Int. Appl., 92 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 9840080	A1	19980917	WO 1998-US4834	19980311 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 6030961	A	20000229	US 1997-814386	19970311 <--
CA 2283162	A1	19980917	CA 1998-2283162	19980311 <--
AU 9864597	A	19980929	AU 1998-64597	19980311 <--
EP 986391	A1	20000322	EP 1998-910333	19980311 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2001514665	T	20010911	JP 1998-539793	19980311 <--
IL 131742	A	20051120	IL 1998-131742	19980311 <--
PRIORITY APPLN. INFO.:			US 1997-814386	A 19970311 <--
			WO 1998-US4834	W 19980311 <--

OTHER SOURCE(S): MARPAT 129:239917

AB Compns. and methods are provided for treating, preventing or ameliorating cancer and other proliferative diseases, as are methods of inducing wound healing, treating cutaneous ulcers, treating gastrointestinal disorders, treating blood disorders such as anemias, immunomodulation, enhancing recombinant gene expression, treating insulin-dependent patients, treating cystic fibrosis patients, inhibiting telomerase activity, treating virus-associated tumors, especially EBV-associated tumors, modulating gene expression and in particular, augmenting expression of tumor suppressor genes, inducing tolerance to antigens, treating, preventing or ameliorating protozoan infection, or inhibiting histone deacetylase in cells. The compns. of the invention are to and the methods of the invention use oxyalkylene phosphate compds.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS

## RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 38 OF 58 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1998:621108 CAPLUS  
 DOCUMENT NUMBER: 129:239914  
 TITLE: Hydroxy- and ether-containing oxyalkylene esters and therapeutic uses thereof  
 INVENTOR(S): Nudelman, Abraham; Rephaeli, Adi  
 PATENT ASSIGNEE(S): Beacon Laboratories, L.L.C., USA  
 SOURCE: PCT Int. Appl., 57 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9840065	A1	19980917	WO 1998-US4764	19980311 <--
W:				
AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:				
GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 6043389	A	20000328	US 1997-814224	19970311 <--
CA 2283173	A1	19980917	CA 1998-2283173	19980311 <--
AU 9865501	A	19980929	AU 1998-65501	19980311 <--
AU 728419	B2	20010111		
EP 998278	A1	20000510	EP 1998-911574	19980311 <--
R:				
AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2001514664	T	20010911	JP 1998-539760	19980311 <--
US 6239176	B1	20010529	US 2000-504786	20000215 <--
PRIORITY APPLN. INFO.:			US 1997-814224	A 19970311 <--
			WO 1998-US4764	W 19980311 <--

OTHER SOURCE(S): MARPAT 129:239914

AB This invention relates to compns. for and methods of treating, preventing or ameliorating cancer and other proliferative diseases as well as methods of inducing wound healing, treating cutaneous ulcers, treating gastrointestinal disorders, treating blood disorders such as anemias, immunomodulation, enhancing recombinant gene expression, treating insulin-dependent patients, treating cystic fibrosis patients, inhibiting telomerase activity, treating virus-associated tumors, especially

EBV-associated tumors, augmenting expression of tumor suppressor genes, inducing tolerance to antigens, or treating, preventing or ameliorating protozoan infection or inhibiting histone deacetylase in cells. The compns. of the invention are to and the methods of the invention use hydroxy and ether-containing oxyalkylene esters.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 39 OF 58 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1998:621086 CAPLUS  
 DOCUMENT NUMBER: 129:239911  
 TITLE: Nitrogen-containing oxyalkylene esters and therapeutic uses thereof  
 INVENTOR(S): Nudelman, Abraham; Rephaeli, Ada  
 PATENT ASSIGNEE(S): Beacon Laboratories, L.L.C., USA  
 SOURCE: PCT Int. Appl., 96 pp.  
 CODEN: PIXXD2

DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9839966	A1	19980917	WO 1998-US4763	19980311 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 6110970	A	20000829	US 1997-814225	19970311 <--
AU 9865500	A	19980929	AU 1998-65500	19980311 <--
EP 973389	A1	20000126	EP 1998-911573	19980311 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRIORITY APPLN. INFO.:			US 1997-814225	A 19970311 <--
			WO 1998-US4763	W 19980311 <--

OTHER SOURCE(S): MARPAT 129:239911

AB Compns. and methods are provided for treating, preventing or ameliorating cancer and other proliferative diseases, as are methods of inducing wound healing, treating cutaneous ulcers, treating gastrointestinal disorders, treating blood disorders such as anemias, immunomodulation, enhancing recombinant gene expression, treating insulin-dependent patients, treating cystic fibrosis patients, inhibiting telomerase activity, treating virus-associated tumors, especially EBV-associated tumors, modulating gene expression and particularly augmenting expression of tumor suppressor genes, inducing tolerance to antigens, treating, preventing or ameliorating protozoan infection or inhibiting histone deacetylase in cells. The compns. of the invention are to and the methods of the invention use nitrogen-containing oxyalkyl esters.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 40 OF 58 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1998:621085 CAPLUS

DOCUMENT NUMBER: 129:255005

TITLE: Unsaturated oxyalkylene esters and therapeutic uses thereof

INVENTOR(S): Neiss, Edward; Loev, Bernard

PATENT ASSIGNEE(S): Beacon Laboratories L.L.C., USA

SOURCE: PCT Int. Appl., 57 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9839965	A1	19980917	WO 1998-US4756	19980311 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM,				

GA, GN, ML, MR, NE, SN, TD, TG				
US 6124495	A	20000926	US 1997-814366	19970311 <--
CA 2283306	A1	19980917	CA 1998-2283306	19980311 <--
AU 9865496	A	19980929	AU 1998-65496	19980311 <--
AU 746268	B2	20020418		
EP 973388	A1	20000126	EP 1998-911569	19980311 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, SI, LT, LV, FI, RO				
US 6599937	B1	20030729	US 2000-669013	20000925 <--
PRIORITY APPLN. INFO.:			US 1997-814366	A 19970311 <--
			WO 1998-US4756	W 19980311 <--

OTHER SOURCE(S): MARPAT 129:255005

AB Compns. and methods are provided for treating, preventing, or ameliorating cancer and other proliferative diseases, are methods of inducing wound healing, treating cutaneous ulcers, treating gastrointestinal disorders, treating blood disorders such as anemias, immunomodulation, enhancing recombinant gene expression, treating insulin-dependent patients, treating cystic fibrosis patients, inhibiting telomerase activity, treating virus-associated tumors, especially EBV-associated tumors, modulating gene expression and particularly augmenting expression of a tumor suppressor gene and inducing tolerance to an antigen. The methods of the invention use unsatd. oxyalkylene esters.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT